A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study

NCT05954429 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fudan University